Skip to main content
In stock|Targeted Therapy

Lorlatinib

Oncology TypeSolid Tumour
Drug Class / MechanismALK / ROS1 / NTRK Inhibitor
No Image
Description

Lorlatinib is classified as an ALK / ROS1 / NTRK Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3